GlassScriptPhysician profile
Hannah W Klein
NPI 1811250418
$2,387.12
in general payments reported to CMS, 2019-2025
34 companies · $246 in 2025
The $246 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.13 · 2020: $168 · 2021: $1,255 · 2022: $17.15 · 2023: $447 · 2024: $214 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $907.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $426.37 | 2020-2024 | Briviact |
| Abbvie INC. | $269.88 | 2023-2025 | |
| Sk Life Science, INC. | $231.75 | 2021-2024 | Xcopri |
| Eisai INC. | $191.81 | 2020-2025 | |
| Livanova USA, INC. | $160.17 | 2019-2021 | |
| Neurelis, INC. | $130.74 | 2020-2021 | |
| Amgen INC. | $122.28 | 2021 | |
| Glaxosmithkline, LLC. | $84.18 | 2024-2025 | Nucala |
| Biohaven Pharmaceuticals, INC. | $69.84 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $53.38 | 2021 | |
| Jazz Pharmaceuticals INC. | $49.76 | 2023 | Epidiolex, Xywav |
| Sunovion Pharmaceuticals INC. | $43.30 | 2021 | |
| Greenwich Biosciences, INC. | $42.07 | 2020-2021 | |
| Aprecia Pharmaceuticals, LLC | $40.25 | 2021 | |
| Genzyme Corporation | $39.08 | 2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $34.05 | 2025 | Lumryz |
| Genentech USA, INC. | $33.92 | 2023 | Ocrevus, Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.89 | 2022-2023 | Ofev |
| Axsome Therapeutics, INC. | $32.10 | 2023-2024 | Sunosi |
| Acadia Pharmaceuticals INC | $27.64 | 2023-2024 | Nuplazid |
| Owp Pharmaceuticals, INC. | $27.56 | 2020-2021 | |
| Aucta Pharmaceuticals, INC. | $27.02 | 2025 | Motpoly Xr |
| Supernus Pharmaceuticals, INC. | $25.83 | 2021 | |
| Biomarin Pharmaceutical INC. | $25.16 | 2021 | |
| Astellas Pharma US INC | $24.03 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.10 | 2024 | Glassia |
| Ge Healthcare | $18.64 | 2024 | |
| Argenx US, INC. | $18.21 | 2025 | Vyvgart Hytrulo, Vyvgart |
| Xeris Pharmaceuticals, INC. | $17.01 | 2024 | Keveyis |
| United Therapeutics Corporation | $15.60 | 2025 | Tyvaso |
| Aquestive Therapeutics, INC. | $14.64 | 2021 | |
| Lilly USA, LLC | $14.15 | 2023 | Emgality, Reyvow |
| Medtronic USA, INC. | $12.00 | 2020 | |
| Biocodex, INC. | $11.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.